Melanoma is a paradigmatic example of the rising cost of cancer treatment due to the incorporation of new high-cost therapies, as shown in a systematic review of nine studies on the cost-effectiveness of treatments for advanced melanoma with the introduction of therapeutic innovations with BRAF and MEK inhibitors and immunotherapy [43]. Here, BRAF is linked to melanoma.